Cryopreservation of Hepatocyte Microbeads for Clinical Transplantation by Jitraruch, Suttiruk et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1177/0963689717720050
Link to publication record in King's Research Portal
Citation for published version (APA):
Jitraruch, S., Dhawan, A., Hughes, R. D., Filippi, C., Lehec, S. C., Glover, L., & Mitry, R. R. (2017).
Cryopreservation of Hepatocyte Microbeads for Clinical Transplantation. Cell Transplantation, 26(8), 1341-1354.
DOI: 10.1177/0963689717720050
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 06. Nov. 2017
Original Article
Cryopreservation of Hepatocyte
Microbeads for Clinical Transplantation
Suttiruk Jitraruch1,2, Anil Dhawan1, Robin D. Hughes1,
Celine Filippi1, Sharon C. Lehec1, Leanne Glover3,
and Ragai R. Mitry1
Abstract
Intraperitoneal transplantation of hepatocyte microbeads is an attractive option for the management of acute liver failure.
Encapsulationof hepatocytes in alginatemicrobeads supports their function and prevents immune attack of the cells. Establishment
of banked cryopreserved hepatocyte microbeads is important for emergency use. The aim of this study was to develop an
optimized protocol for cryopreservation of hepatocyte microbeads for clinical transplantation using modified freezing solutions.
Four freezing solutions with potential for clinical application were investigated. Human and rat hepatocytes cryopreserved with
University of Wisconsin (UW)/10% dimethyl sulfoxide (DMSO)/5% (300 mM) glucose and CryoStor CS10 showed better post-
thawing cell viability, attachment, and hepatocyte functions than with histidine–tryptophan–ketoglutarate/10% DMSO/5% glucose
andBambanker. The 2 freezing solutions that gave better resultswere studiedwith human and rat hepatocytesmicrobeads. Similar
effects on cryopreserved microbead morphology (external and ultrastructural), viability, and hepatocyte-functions post thawing
wereobservedover 7 d in culture. UW/DMSO/glucose, as a basal freezingmedium,was used to investigate the additional effects of
cytoprotectants: a pan-caspase inhibitor (benzyloxycarbonyl-Val-Ala-DL-Asp-fluoromethylketone [ZVAD]), an antioxidant (des-
feroxamine [DFO]), and a buffering and mechanical protectant (human serum albumin [HSA]) on RMBs. ZVAD (60 mM) had a
beneficial effect on cell viability thatwas greater thanwithDFO (1mM),HSA (2%), and basal freezingmediumalone. Improvements
in the ultrastructure of encapsulated hepatocytes and a lower degree of cell apoptosis were observed with all 3 cytoprotectants,
withZVADtending toprovide the greatest effect. CytochromeP450 activitywas significantly higher in the 3 cytoprotectant groups
than with fresh microbeads. In conclusion, developing an optimized cryopreservation protocol by adding cytoprotectants such as
ZVAD could improve the outcome of cryopreserved hepatocyte microbeads for future clinical use.
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Introduction
Acute liver failure (ALF) is a rare but life-threatening con-
dition without liver transplantation. However, the tremen-
dous regenerative capacity of the liver enables spontaneous
recovery, avoiding liver transplantation and lifelong immu-
nosuppression. Current liver support systems like Molecular
Adsorbent Recirculation System1 and the fractionated
plasma separation and absorption system (Prometheus1) do
not provide any synthetic function while nonselective
exchange of biological fluid could lead to low liver trophic
factors negatively affecting regeneration.1-3 Transplantation
of alginate microencapsulated hepatocytes (microbeads) has
been studied in animal models of ALF with promising out-
comes.4-7 Hepatocyte microbeads can replace the missing
detoxification and synthetic functions of damaged hepato-
cytes either for a short period, bridging the patient to liver
transplantation, or allowing time for the liver to regenerate
and recover, avoiding liver transplantation altogether.
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Cryopreservation of hepatocytes is a key to cell therapy
for emergency transplantation in patients with ALF. Estab-
lishment of banked cryopreserved hepatocyte microbeads
for long-term storage would be of great benefit, allowing
on-demand usage for emergency cases. However, the diffi-
culty with cryopreservation is due to cells being subjected to
damaging conditions during both freezing and thawing steps.
Previously published studies have shown protective effects
of alginate microencapsulation on hepatocytes during the cryo-
preservation process.8-11 The challenges are the high water con-
tent (>90%) together with the relatively large size of the
microbeads and the number of cells compared to single cells.
This makes microbeads susceptible to cryodamage by ice-
crystal formation, leading to cell death.12 Studies on cryopreser-
vation of microencapsulated cells have been reported with vari-
able effectiveness related to differences in cryopreservation
methods. Most of the previous studies of cryopreservation of
microencapsulated hepatocytes used a cryopreservation
medium consisting of culture medium, 10% fetal calf serum
(FCS), and 10% dimethyl sulfoxide (DMSO) placed into cryo-
vials and stored in liquid nitrogen.8-10,13 Although some of these
protocols provided relatively good viability and function after
thawing, they are not acceptable for clinical transplantation.
Recent studies demonstrated that apoptosis plays an impor-
tant role in cryopreservation-induced cell injury.14,15 The
understanding of pathways involved with cryopreservation-
induced molecular cell death could lead to improvement in
the cryopreservation outcome, as cytoprotectants can be
added to specifically target or control the apoptosis pathway.
Apoptosis signal transduction can be initiated at different lev-
els (cell membrane or mitochondria) but is then followed by
common proteolytic caspase cascade pathways (caspase-8, -9,
and -3).16 The pan-caspase inhibitor benzyloxycarbonyl-Val-
Ala- DL-Asp-fluoromethylketone (ZVAD) has been shown to
have beneficial effects on cell viability and function under
stressful conditions prone to apoptosis such as isolation and
cryopreservation of encapsulated hepatocytes.11,17
The hypothesis of this study was that cryopreservation of
hepatocyte microbeads could be improved by using an appro-
priate freezing solution with added cytoprotective agents such
as the anti-apoptosis compound ZVAD, an iron chelator such
as desferoxamine (DFO), and human serum albumin (HSA) to
protect hepatocytes from oxidative stress and apoptosis15,18,19
and maintain microbead integrity.20 The aim of this study was
to develop an optimized protocol for cryopreservation of
human hepatocyte microbeads (HMBs) for clinical transplan-
tation. Stepwise studies of different types of cryopreservation
solutions and cytoprotectants that can potentially be used for
clinical application were investigated.
Materials and Methods
Experimental Design
Firstly, the effects of 4 different freezing solutions were eval-
uated on isolated human and rat hepatocytes. The 2 freezing
solutions that resulted in the greatest cell viability and func-
tion after thawing were then selected for study with HMBs
and rat hepatocyte microbeads (RMBs), respectively, cryopre-
servation. Following this, cytoprotectants were added in order
to improve the microbead cryopreservation protocol.
Hepatocytes were isolated from the same donor tissues
for each set of experiments. Fresh isolated cells and
microbeads were prepared identically and maintained in
cultures as cryopreserved samples. All assays on cryopre-
served samples were performed and compared to fresh
samples at similar time points.
Hepatocyte Isolation
Human hepatocyte isolation. Human hepatocytes were isolated
from donor liver tissues (rejected or unused for transplanta-
tion) or from the nontumoral margin of liver resections from
metastatic cancer cases using a collagenase perfusion tech-
nique according to Mitry.21 Total hepatocyte number and
their viability were estimated using the standard trypan blue
(Sigma-Aldrich, Dorset, UK) exclusion test; cell viability
was 60%. All human tissues were approved for research
use in accordance with the Research Ethics Committee of
King’s College Hospital. Written informed consent was
obtained from donor relatives or patients.
Rat hepatocyte isolation. Male Sprague Dawley (Harlan Olec,
Bicester, UK) rats (8–10 wks old and weighed between 200 g
and 300 g) were used as hepatocyte donors. Animals were
maintained in conventional housing facilities and received
standard care. They were housed in a room kept at 21+ 2 C,
humidity of 55% + 10% and 12-h light–dark cycle with ad
libitum food and water for 1 wk prior to the procedure. All
animal donors were handled following protocols approved by
the ethical review process of King’s College London in accor-
dance with the UK Animals (Scientific) Procedures Act of 1986.
Rat hepatocyte isolation was performed using in situ collagenase
perfusion of the liver as previously described.22,23 The total
number of hepatocytes and viability were determined using the
standard trypan blue exclusion test.
Encapsulation of Hepatocytes
Human and rat hepatocytes were encapsulated using the
optimized technique described by Jitraruch et al.,4 where the
microbeads were produced at a cell density of 3.5 106 cell/
mL alginate and polymerized for 15 min. Briefly, hepatocyte
microbeads were produced using the IE-50R encapsulator
(Inotech Encapsulation AG, Dottikon, Switzerland) and ster-
ile clinical grade reagents. Ultrapure sodium alginate, with
low-viscosity and high-glucoronic acid (PRONOVA™
SLG20; NovaMatrix, Sandvika, Norway) was dissolved in
0.9% NaCl to give a final concentration of 1.5% alginate
solution (w/v). Microbeads were produced using a 250-mm
nozzle and polymerized in 1.2% CaCl2 solution. The
microbeads were washed twice with 0.9% NaCl to remove
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excess Ca2þ ions. The microbeads size was 500 + 100 mm,
containing approximately 450 cells/beads.
Cryopreservation of Hepatocytes in Different Freezing
Solutions
Human and rat hepatocytes were used to evaluate 4 different
cryopreservation media consisting of (a) 2 hypothermic
organ preservation solutions namely University of Wiscon-
sin (UW, Bristol-Myers Squibb AB, Hounslow, UK) and
histidine–tryptophan–ketoglutarate (HTK: Custodiol™; Dr.
Franz Kohler Chemie GMB, Alsbach-Ha¨hnlein, Germany)
and (b) 2 commercial cryopreservation solutions which are
Bambanker (Nippon Genetics, Tokyo, Japan) and CryoStor
CS10™ (Sigma-Aldrich). All cryopreservation solutions
contained 10% DMSO (WAK-Chemie Medical GmbH,
Steinbach, Germany). Based on published and standard pro-
tocols used for cryopreservation of human hepatocytes at
King’s College Hospital,24 5% glucose (300mM) was added
to UW and HTK (Table 1). Briefly, isolated hepatocytes
were split into 4 groups. In each group, hepatocytes were
resuspended in ice-cold freezing medium at a density of 1 
107 cells/mL. Hepatocyte suspension was then transferred
into 2-mL cryovials. Cryopreservation was performed using
the standard freezing protocol at King’s College Hospital in
a controlled rate freezer (CRF, Planer, Model: Kryo10 CRF;
Planer PLC, Middlesex, UK).
Cryopreservation of Hepatocyte Microbeads Using
Different Freezing Solutions
The 2 best freezing solutions were further evaluated for
cryopreservation of hepatocyte microbeads (HMBs and
RMBs). Each ice-cold freezing medium was slowly added
to the microbeads (1-mL microbeads þ 4-mL freezing solu-
tion in a 5-mL cryovial). The microbead suspensions were
then maintained on ice for 15–30 min before transfer to the
CRF. The freezing protocol was chosen based on results of a
preliminary study. The published protocols by Terry et al.24
for cryopreservation of human hepatocytes and the protocol
for freezing alginate-encapsulated liver cell spheroids by
Massie et al.25 were compared. These 2 protocols are multi-
step with slow cooling and contain an important holding step
to allow samples to reach equilibrium followed by a shock
cooling step (from 8 C to28 C) to control nucleation of
ice. They are different in terms of starting temperature (8 C
vs. 0 C) and total duration of cryopreservation (62 min vs.
39 min; Table 2). The findings from a pilot study showed
that HMBs cryopreserved according to the Massie et al.’s
protocol provided intact microbeads and higher 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
Table 1. Cryopreservation Solution Mixtures.
Main Solution UW (ViaSpan1) HTK (Custodiol™) Bambankera CryoStor CS10a
Application Organ preservation solution Organ preservation solution Cell cryopreservation medium Cell cryopreservation medium
Ingredients Kþ-lactobionate (100 mM)
KH2PO4 (25 mM)
Naþ (30 mM)
Raffinose (30 mM)
Adenosine (5 mM)
Glutathione (3 mM)
Allopurinol (1 mM)
Hydroxyethyl starch (50 g/L)
Dexamethasone (8 mg/L)
Penicillin (200,000 U/L)
Insulin (40 U/L)
Osmolarity 320 mOsM
pH 7.4
Naþ (15 mM)
Kþ (10 mM)
Mg2þ (4 mM)
Ca2þ (0.015)
Cl (50 mM)
L-Histidine (198 mM)
Ketoglutarate (1 mM)
Tryptophan (2 mM)
Mannitol (30 mM)
Osmolarity 310 mOsM
pH 7.2
Ready to use
Serum free
DMSO (10%)
Ready to use
Serum free
DMSO (10%)
[Modified from HTS]
Composition of HTS:
Naþ (100 mM)
Kþ (42.5 mM)
Mg2þ (5 mM)
Ca2þ (0.05 mM)
Cl (17.1 mM)
H2PO4
 (10 mM)
HCO3
 (5 mM)
HEPES (25 mM)
Lactobionate (100 mM)
Sucrose (20mM)
Mannitol (20mM)
Glucose (5 mM)
Dextran-40 (6%)
Adenosine (2 mM)
Glutathione (3 mM)
Osmolarity 360 mOsM
pH 7.6
Additives
DMSO 10% 10% — —
Glucose 5% 5% — —
Note. UW, University of Wisconsin solution; HTK, histidine, tryptophan, ketoglutarate solution; HTS, hypothermosol; DMSO, dimethyl sulfoxide.
aThe actual composition of Bambanker and CryoStor CS10 are undisclosed.
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(MTT) activity and albumin production at day 1 and 3 post
thawing than those cryopreserved with the standard protocol
for hepatocytes by Terry et al.24 As a result, the freezing
protocol by Massie et al. was applied in all of the following
experiments of microbead cryopreservation.
Effect of Cytoprotectants on Hepatocyte Microbeads
The cytoprotectant compounds were chosen based on pub-
lished data which demonstrated beneficial effects during
culture, cold storage, or cryopreservation of cells or micro-
encapsulated cells. Compounds that have different mechan-
isms to protect cells, including a caspase inhibitor (ZVAD),
an iron chelator (DFO), and HSA, were evaluated. The con-
centrations used in current study were based on those used
previously (ZVAD; R&D Systems, Abington, UK) at
60 mM,11,17 DFO (Sigma-Aldrich) at 1 mM,19,26 and HSA
(20%; Baxter Healthcare UK, Berkshire, UK) at 2%.20,27
The effects of the compounds were tested on RMBs by add-
ing them to the most effective freezing medium from the
above experiments. There were 4 experimental groups: (1)
basal freezing media alone, (2) basal freezing media with
HSA, (3) basal freezing media with DFO, and (4) basal
freezing media with ZVAD. Microbead suspensions were
then processed and cryopreserved as described above.
Thawing and Culturing Cryopreserved Cells and
Microbeads
Following storage at 140 C for 2 wk, isolated cells and
microbeads were rapidly thawed in a 37 C water bath24,28
using ice-cold Eagle’s minimum essential medium (EMEM)
(EMEM; Lonza, Verviers, Belgium) as thawing media.
Similarly, cryopreserved HMBs were thawed with 2%
(v/v) HSA added in EMEM. Thawed hepatocytes were then
plated and cultured in William’s E medium (WEM;
Sigma-Aldrich) supplemented with 10% FCS (Invitrogen,
Paisley, UK), 10-mM 4-(2-hydroxyethyl)-1-piperazine-
ethanesulfonic acid (HEPES; Lonza), 2-mM L-glutamine
(Sigma-Aldrich), 0.1-mM dexamethasone (Sigma-Aldrich),
0.1-mM insulin (Sigma-Aldrich), penicillin (50 U/mL;
Sigma-Aldrich), and streptomycin (50 mg/mL; Sigma-
Aldrich). Thawed microbeads were cultured in the same
medium as the same as hepatocytes except Connaught Med-
ical Research Laboratories medium (Mediatech was used,
Inc., Vancouver, Canada) instead of WEM without HEPES.
The cells and microbeads were maintained in a humidified
incubator at 37 C, 5% CO2 for 7 d.
Plated Hepatocyte Viability and Function
Cell viability was determined immediately after thawing
using the trypan blue exclusion test. Mitochondrial dehydro-
genase activity, cell attachment, and hepatocyte specific
function were evaluated after maintenance in culture for
24 h. For mitochondrial dehydrogenase activity and cell
attachment assay, cells were cultured in collagen-coated
96-well plates (5.0  104 cells/well). The mitochondrial
dehydrogenase activity of hepatocytes was assessed using
an MTT assay.29 Hepatocyte attachment was assessed using
the sulforhodamine B (SRB) assay.30 Albumin and urea
synthesis were assessed for cells cultured in collagen-
coated 24-well plates (3.0  105 cells/well). Albumin pro-
duction was quantified in supernatant using human or rat
albumin enzyme-linked immunosorbent assay (ELISA)
quantitation kits (Bethyl Laboratories, Montgomery, TX,
USA). Urea synthesis was assessed after challenging hepa-
tocytes with ammonium chloride (5 mM) for 6 h at 37 C.
Supernatant was collected and analyzed using the
QuantiChrom™ Urea Assay Kit (BioAssay Systems, Hay-
ward, CA, USA).
Hepatocyte Microbead Viability and Function
Viability and function of microbeads (HMBs and RMBs)
were assessed according to Jitraruch et al.4 immediately
postthaw (day 0), day 1, day 3, and day 7. Briefly, viability
of hepatocyte microbeads was evaluated by a cell membrane
integrity assay using 10-mg fluorescein diacetate (FDA;
Sigma-Aldrich, Gilingham, UK) and 20-mg propidium
iodide (PI; Sigma-Aldrich) incubated in the dark for 90 s
then visualized under a fluorescent microscope (Leica
Microsystems Ltd, Milton Keynes, UK). In addition, an
MTT assay was performed to assess overall metabolic activ-
ity of encapsulated hepatocytes. Hepatocyte specific func-
tions of microbeads including of albumin production, urea
synthesis, and cytochrome P450 (CYP1A1/2) were studied
in supernatants on day 1, day 3, and day 7. The amount of
Table 2. Multistep Slow-cooling Cryopreservation Protocols
Using Controlled Rate Freezer.
Step
Start
Temperature Rate Time
End
Temperature
Protocol for human hepatocytes24
1 8 C 1 C/min 8 min 0 C
2 0 C Hold 8 min 0 C
3 0 C 2 C/min 4 min 8 C
4 8 C 35 C/min 33 s 28 C
5 28 C 2.5 C/min 2 min 33 C
6 33 C þ2.5 C /min 2 min 28 C
7 28 C 1 C/min 32 min 60 C
8 60 C 10 C/min 4 min 100 C
9 100 C 20 C/min 2 min 140 C
Protocol for encapsulated liver spheroids25
1 0 C Hold 8 min 0 C
2 0 C 2 C/min 4 min 8 C
3 8 C 35 C/min 6 s 28 C
4 28 C 2.5 C/min 2 min 33 C
5 33 C þ2.5 C/min 2 min 28 C
6 28 C 2 C/min 16 min 60 C
7 60 C 10 C/min 4 min 100 C
8 100 C 20 C/min 3 min 160 C
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albumin and urea secreted by HMBs and RMBs were eval-
uated by the same method as for isolated cells. CYP1A1/2
activity was measured using the ethoxyresorufin-O-
deethylase method.31
Morphological Examination Using Light Microscopy
The morphology of hepatocytes from each group was exam-
ined after thawing and plating on collagen-coated plates for
24 h. Microbead morphology was evaluated immediately
post thawing.
Hepatocyte Microbead Ultrastructure Examination
Using Electron Microscopy
The exterior and interior ultrastructural morphology of
hepatocyte microbeads were studied using scanning elec-
tron microscopy (SEM) and transmission electron micro-
scopy (TEM). Microbeads were processed at the Centre for
Ultrastructural Imaging, King’s College London. Briefly,
samples were fixed overnight with 2.5% glutaraldehyde in
0.15 M cacodylate buffer (pH 7.3) at 4 C. For SEM, after
the initial fixation, samples were rinsed several times in
cacodylate buffer and postfixed with 1% osmium tetroxide
in 0.15 M cacodylate buffer (pH 7.3) for 1 h. Samples were
then washed and dehydrated in a graded series of ethanol
and dried by hexamethyldislazane. Dried samples were
mounted on stubs (Hitachi; NanoAndMore GmbH,
Wetzlar, Germany) with adhesive carbon tab (TAAB) and
sputter coated with gold (Emitech K550X; Quorum Tech-
nologies Ltd, East Sussex, UK) before examination under
an SEM. Images recorded using an FEI Quanta 200F field
emission SEM (FEI Company, Hillsboro, OR, USA) operated
at 5 kV in high vacuum mode.
For TEM, after the initial fixation, samples were rinsed sev-
eral times in cacodylate buffer and postfixed with 1% osmium
tetroxide in 0.15 M cacodylate buffer (pH 7.3) for 1.5 h. Samples
were then washed, dehydrated in a graded series of ethanol
solutions, and equilibrated with propylene oxide before infiltra-
tion with SPURR resin (TAAB). Samples were embedded and
polymerized at 70 C for 24 h. Ultrathin sections (70–90 nm)
were prepared using a Reichert-Jung Ultracut E Ultramicrotome
(Reichert-Jung, Vienna, Austria), mounted on 150 mesh copper
grids, contrasted using uranyl acetate and lead citrate, and exam-
ined on an FEI Tecnai 12 transmission microscope (FEI Com-
pany, USA) operated at 120 kV. Images were acquired with an
AMT 16000M digital camera (Advanced Microscopy Tech-
niques, Corp., Woburn, MA, USA).
Detection of Apoptotic Cells Using Flow Cytometry
Cryopreserved hepatocyte microbeads from the 4 groups of
the cytoprotectant study (1 mL/group) were thawed and cul-
tured in 6-well plates. Additional samples of hepatocyte
microbeads cryopreserved in freezing solution without any
cryoprotectant were thawed and then incubated with ZVAD
(60 mM) for 30 min prior to culture. After 24 h in culture,
hepatocytes were released from the microbeads.32 Cells were
then washed twice with phosphate-buffered saline (PBS)/1%
FCS followed by PI staining. Stained cells were incubated at
4 C for 30 min in the dark, then washed with PBS/1% FCS,
and resuspended in 400-mL PBS/1% FCS. An equivalent
number of cells from each sample were acquired for
fluorescence-activated cell sorting (FACS) analysis (FACS-
Canto II, BD Biosciences, San Jose, CA). FACS was set to
detect PI fluorescence at 620 + 10 nm.
Statistical Analysis
Data were analyzed using GraphPad Prism1 6 software
(GraphPad, San Diego, CA, USA). All data are presented
as the mean + standard deviation (SD) from at least 4
independent experiments. Student t-tests were applied to
compare 2 independent groups. Comparisons between 3
or more groups with 1 independent variable were per-
formed using one-way analysis of variance (ANOVA) and
multiple comparisons were adjusted by using the Tukey’s
post hoc test. A two-way repeated measurement ANOVA
and Tukey’s post hoc multiple comparisons tests were used
to compare groups exposed to different conditions. A P
value of 0.05 was considered statistically significant.
Results
Effect of Freezing Solutions on Hepatocytes
Cell viability of fresh human hepatocytes was assessed by
trypan blue immediately after isolation, and overall mito-
chondrial activity was assessed immediately after plating
by MTT assay (77.0% + 7.3% and 1.13 + 0.69 optical
density (OD) reading units, respectively). There was a sig-
nificant decrease in cell viability evaluated immediately
after thawing and after plating with all freezing media com-
pared to fresh cells (trypan blue: P < 0.05 and MTT assay: P
< 0.001). There was no significant difference in postthawing
viability between cells cryopreserved with the 4 different
solutions (CryoStor CS10: 57.3% + 13.9%, Bambanker:
54.7%+ 10.3%, UW/DMSO/glucose: 50.4%+ 10.8%, and
HTK/DMSO/glucose: 44.5% + 12.7%). Cell attachment
(SRB assay) of cryopreserved cells was significantly lower
than that of fresh cells and showed a similar trend to that
observed with cell viability. However, the UW/DMSO/glu-
cose group had the highest attachment efficacy (0.35+ 0.21
OD reading units), but this did not reach statistical signifi-
cance (Fig. 1A–C). The typical hexagonal shape of hepato-
cytes was observed in cryopreserved cells under light
microscopy. There was no obvious difference in morpholo-
gical appearance between cryopreserved groups, except in
the Bambanker group which showed some “damaged” hepa-
tocytes with irregular cell shape (Fig. 2). Comparison of
albumin synthesis between fresh and cryopreserved groups
showed a minimal decrease with no statistically significant
difference. Nevertheless, urea synthesis was significantly
Jitraruch et al 1345
reduced in HTK/DMSO/glucose cryopreserved cells com-
pared to fresh cells (P ¼ 0.04; Fig. 1D, E).
The results obtained from experiments using rat
hepatocytes showed a similar outcome to human hepato-
cytes. Comparing cryopreserved cells, the CryoStor CS10
group (54.0% + 5.70%) demonstrated significantly higher
cell viability than Bambanker (P ¼ 0.003), HTK/DMSO/
glucose (P ¼ 0.002), or UW/DMSO/glucose (P ¼ 0.04).
Cells cryopreserved in UW/DMSO/glucose were able to
maintain their overall mitochondrial activity and attachment
after plating and culturing for 24 h better than the other 3
groups. CryoStor CS10 and UW/DMSO/glucose showed a
Fig. 1. Effects of cryopreservation using the 4 different freezing solutions on human hepatocytes viability and function (N ¼ 6). (A) Cell
viability immediately after thawing assessed by trypan blue exclusion, (B) cell viability assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assay, (C) cell attachment assessed by sulforhodamine B assay, (D) albumin production, and (E) urea synthesis
after thawed and plated for 24 h. Statistical significance as compared to fresh hepatocytes (controls): *P < 0.05, **P < 0.01, and ***P < 0.001.
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promising outcome in both human and rat hepatocytes.
Hence, these 2 freezing solutions were chosen for the study
of cryopreservation of microbeads.
Effect of Freezing Solutions on Hepatocyte Microbeads
There was no significant difference between cell viability of
cryopreserved HMBs immediately postthawing and after
maintenance in culture for 7 d, as assessed by FDA/PI (data
not shown) and MTT assay (Fig. 3A). Hepatocyte function
of cryopreserved HMBs was assessed by albumin produc-
tion, urea synthesis, and CYP1A1/2; comparable results
between the 2 freezing solutions were observed (Fig. 3B–
D). Interestingly, there was a small difference in cell viabi-
lity and functionality of cryopreserved HMBs after thawing
and then after maintenance in culture throughout the 7 d,
while fresh HMBs showed a significant decrease in cell
viability and urea production. When comparing fresh and
cryopreserved HMBs, there was a significant decrease in
both viability and urea synthesis in cryopreserved HMBs.
These reductions were more apparent immediately after
thawing and on day 1 in culture (P < 0.0001) than on days
3 and 7. However, albumin production was unexpectedly
significantly higher in cryopreserved HMBs in both groups
than those of fresh cells at each time point (P  0.01). In
contrast, there was no significant difference in CYP1A1/2
activity between fresh and cryopreserved HMBs.
Similar effects of freezing solutions on HMBs were also
observed in RMBs; there were no significant differences
found between UW/DMSO/glucose and CryoStor CS10
(Fig. 4). However, the difference between fresh and cryo-
preserved RMBs was more prominent than in the HMB
experimental groups.
The morphology of cryopreserved microbeads (HMBs
and RMBs) was examined under light microscopy and SEM.
The morphologies were intact and well-preserved when
Fig. 2. Representative images of human hepatocyte morphology after plating and maintenance in culture for 24 h (under light microscopy;
400), (A) fresh hepatocytes (control). Cryopreserved hepatocytes using (B) University of Wisconsin solution/dimethyl sulfoxide (DMSO)/
glucose, (C) CryoStorCS10, (D) histidine–tryptophan–ketoglutarate/DMSO/glucose, and (E) Bambanker.
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Fig. 3. Effects of 2 freezing solutions on cell viability and function of human hepatocyte microbeads (HMBs) after thawing and maintenance in
culture for 7 d (N¼ 4); (A) cell viability, (B) albumin production, (C) urea synthesis, and (D) cytochrome P450 activity. Statistical significance:
*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. Statistical significance compared to fresh HMBs: #P < 0.05, ##P < 0.01, ###P < 0.001,
and ####P < 0.0001.
Fig. 4. Effects of 2 freezing solutions on cell viability and function of rat hepatocyte microbeads after thawing and 7 d maintenance in culture
(N ¼ 4). (A) Cell viability, (B) albumin production, (C) urea synthesis, and (D) cytochrome P450 family activity. Statistical significance
compared to either immediately post thawing or compared to day 1: *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 and compared to
fresh human hepatocyte microbeads: #P < 0.05 and ##P < 0.01, ###P < 0.001 and ####P < 0.0001.
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compared to fresh samples. However, further investigation
of the ultrastructure of hepatocytes within microbeads using
TEM showed that microbeads cryopreserved in CryoStor
CS10 provided slightly more cells with preserved ultrastruc-
ture than those in UW/DMSO/glucose. Figure 5 shows TEM
images of examples of healthy hepatocytes versus necrotic
and apoptotic hepatocytes within microbeads. Healthy hepa-
tocytes exhibited well-defined nuclear membranes and con-
tained abundant smooth membranes with intact cristae in
mitochondria. In contrast, apoptotic hepatocytes showed
condensation of nuclear chromatin, irregular plasma
membranes, and swelling mitochondria. Overall, UW/
DMSO/glucose and CryoStor CS10 had similar effects on
cryopreservation of hepatocyte microbeads. Therefore, UW/
DMSO/glucose which is the freezing media used for cryo-
preservation of clinical grade human hepatocytes was chosen
as the freezing solution in further cryopreservation
experiments.
Effects of Cytoprotectants on Hepatocyte Microbeads
RMBs cryopreserved in UW/DMSO/glucose (basal freezing
medium) containing 60-mM ZVAD resulted in a signifi-
cantly higher cell viability immediately post thawing
(MTT¼ 6.12+ 2.24 OD reading/100-mg RMBs) than those
cryopreserved with standard basal freezing medium alone
(3.51 + 0.62, P ¼ 0.002). After 1 d in culture, the cell
viability of the ZVAD group (5.79 + 1.16) remained sig-
nificantly higher than that of basal medium alone (2.42 +
0.90, P < 0.0001), the DFO group (3.39+ 0.98, P ¼ 0.006),
or the fresh RMBs (3.41 + 0.88, P ¼ 0.007). Moreover,
RMBs in the HSA group gave significantly higher viability
(4.48 + 2.22, P ¼ 0.006) than those in the basal medium
group. Interestingly, fresh RMBs gave better viability com-
pared to the other groups (P < 0.0001) on the day of produc-
tion (day 0) but had similar viability at days 3 and 7 (Fig.
6A). The results of cell viability assessed by fluorescence
staining correlated well with the MTT assay data.
There were no significant differences between
hepatocyte-specific functions in the 4 RMB cryopreserved
groups. The fresh RMBs had significantly higher albumin
production at day 1 (P < 0.0001) and day 3 (P < 0.0001)
compared to the other 4 groups. At day 7, albumin synthesis
of the fresh RMB group (1,331 + 111.6 ng/mg protein)
remained higher than those of the basal medium (950.3 +
209.6, P ¼ 0.03) or HSA (943.9 + 97.0, P ¼ 0.02) groups
but was not significantly different compared to both the DFO
(1,017 + 101.2) and ZVAD (1,061 + 215.2) groups.
Fig. 5. Transmission electron microscopy (TEM) of hepatocytes within microbeads after 24-h culture. Representative TEM images of
normal healthy hepatocytes (left panel) and necrotic/apoptotic hepatocytes (right panel). (A, B) at magnification of 1,400, and (C, D) at high
magnification of 4,800. cNC, condensed nuclear chromatin; G, Golgi apparatus; Ld, lipid droplet; Ly, lysosomes, Mt, mitochondria; N,
nuclei; Nu, nucleoli; Nm, nuclear membrane; Pm, plasma membrane; RER, rough-surfaced endoplasmic reticulum; sMt, swelling mitochon-
dria; V, vacuole.
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Similar findings were observed in urea production, where the
fresh RMB group provided significantly higher production at
day 1 than all of the other groups (P < 0.0001), but not on
days 3 and 7. Interestingly, on day 3, there was significantly
higher CYP1A1/2 activity in RMBs cryopreserved using
HSA (20.7 + 5.0 pmol/mg protein/min, P ¼ 0.001), DFO
(20.6+ 4.0, P¼ 0.001), and ZVAD (20.0+ 3.8, P¼ 0.003)
compared to fresh RMBs (15.1 + 5.2; Fig. 6B–D).
Among the cryopreserved RMB groups, the ZVAD group
had the highest percentage of well-preserved hepatocyte
ultrastructure within microbeads (76.9% of the fresh RMBs
group), followed by the HSA, the DFO, and the basal
medium groups, at 67.4%, 44.7%, and 34.8% of the fresh
RMB group, respectively.
Detection of Apoptotic Cells in Cryopreserved RMBs
The anti-apoptotic effects of cytoprotectants on RMBs were
assessed by detection of the sub-G1 phase of the cell cycle
using PI staining and FACS analysis. Apoptotic cells (frag-
mented nuclei) were arrested in the sub-G1 cycle. RMBs in
the basal medium alone had the highest percentage of cell in
sub-G1 stage (40.1%), whereas the lowest was detected in
the ZVAD group (12.6%). Noticeably, the sub-G1 arrest of
RMBs in the basal medium alone was decreased to 19.3%
when incubated with ZVAD (60 mM) for 30 min immedi-
ately after thawing before maintenance in culture. Figure 7
shows representative FACS histograms of cell populations
after thawing and maintenance in culture for 24 h.
Discussion
This study focused on optimizing cryopreservation solutions
that can potentially be used for cryopreservation of clinical
grade microbeads. The study investigated the effect of cryo-
preservation solutions on cell viability and function of cryo-
preserved hepatocyte microbeads. The important issue was
the scarcity of good quality donor livers for hepatocyte iso-
lation; our study was carried out in a stepwise strategy to
address this problem. Firstly, the efficacy of freezing solu-
tions was compared on both isolated human and rat hepato-
cytes, followed by testing of human and rat microbeads. The
results obtained from these initial experiments demonstrated
comparable outcomes for both human and rat hepatocytes.
Therefore, RMBs were considered suitable for further
experiments to assess cryoprotectants.
In the initial experiments, we attempted to determine the
efficacy of basal freezing solutions for cryopreservation of
isolated hepatocytes. The results showed that these freezing
media alone did not have significantly different effects on
the outcome of cryopreservation. Nevertheless, UW/DMSO/
glucose and CryoStor CS10 were superior to both HTK/
DMSO/glucose and Bambanker for cryopreservation of
hepatocyte suspensions. Hepatocyte cryopreservation in
UW/DMSO/glucose tended to result in higher cell attach-
ment and overall mitochondrial activity after 24 h in culture,
while in CryoStor CS10, cells had a higher viability imme-
diately postthawing. This could be explained by solutions
containing similar compounds that are beneficial for
Fig. 6. Effect of cryopreservation with different cytoprotectants on
viability and hepatocyte-specific functions of rat hepatocyte
microbeads after thawing and maintenance in culture for 7 d
(N ¼ 4). (A) Cell viability, (B) albumin production, (C) urea synth-
esis, and (D) cytochrome P450 family activity. Statistical signifi-
cance: *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
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protection of the cells during cryopreservation (Table 1).
UW has shown beneficial effects for cryopreservation of
hepatocytes,33-36 as it includes important components to pre-
vent cells from swelling, stabilizes cell membranes, and pro-
motes adenosine triphosphate (ATP) production. Moreover,
addition of a high concentration of glucose (300 mM)
enhances the efficacy of UW, so that it leads to an increase
in cell ATP content and protects cell attachment molecules
on the plasma membrane, resulting in better hepatocyte
mitochondrial function and improvement of cell attachment,
respectively.24,37 CryoStor CS10 is a recently developed
freezing solution that has been used clinically for stem cell
banking.38 It was developed from hypothermosol solution
consisting of multiple components to maintain ionic and
osmotic balance under hypothermic conditions. It reduces
cryopreservation-induced delayed-onset cell death, which
develops over time postthawing.14 However, it contains a
low level of glucose (5 mM) to provide energy for the cells.
Extra glucose was not added either to CryoStor CS10 or to
Bambanker, as they are ready-made cryopreservation solu-
tions and their actual ingredients are not disclosed by the
suppliers, and addition of glucose may have led to unex-
pected interaction(s).
The HTK-based freezing solution used in this study was
the least effective for cryopreservation of both human and rat
hepatocytes. This finding supports previously published
studies demonstrating the superiority of UW solution
over HTK solutions for cold storage of human hepatocytes
and rat livers by limiting cell necrosis and mitochondrial
dysfunction.39,40 Of note, the histidine and phosphate
(buffering system) in HTK have been suggested to be the
cause of toxicity to cells during cold storage.41
Fig. 7. Representative histograms of cell cycle analysis using fluorescence activated cell sorting (FACS). Cryopreserved rat hepatocyte
microbeads were thawed and then cultured for 24 h. Hepatocytes were released from microbeads and analyzed using propidium iodide
staining and FACs.
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Bambanker provided good results for freezing a wide
variety of cells including human gastric epithelial cells,
human T cells, and stem cells.42-44 However, there was no
study using Bambanker for cryopreservation of hepatocytes.
The current results showed that Bambanker is not suitable
for hepatocyte cryopreservation, as it causes some damage to
hepatocytes and abnormal cell morphology after thawing.
The possible explanation for this is not known, as the actual
composition of this solution is not disclosed.
UW/DMSO/glucose and CryoStor CS10 were further
studied in order to compare the efficacy on cryopreservation
of hepatocyte microbeads. The results showed that there
were no significant differences between CryoStor CS10 and
UW/DMSO/glucose with either cryopreserved HMBs or
RMBs. Both freezing solutions were able to maintain
microbead integrity after thawing. Morphology under light
microscopy and SEM indicated that the appearance of cryo-
preserved microbeads was comparable to fresh microbeads.
This suggested that alginate microbeads could be cryopre-
served with 10% DMSO using a multistep, slow-freezing
step protocol without damaging microbead integrity. Cryo-
preserved microbeads with a DMSO concentration lower
than 10% or higher at 25% using a rapid cooling protocol
resulted in low postthawing viability and damage to
microbeads.12,45 Noticeably, viability and functionality of
microbeads after thawing were dramatically decreased com-
pared to fresh microbeads in this stage of study. This indi-
cated that these 2 freezing media for cryopreservation of
hepatocyte microbeads were not sufficient to protect cells
against cell death related to cryopreservation. However,
CYP1A1/2 activities were well-preserved and showed min-
imal reduction compared to fresh microbeads. It has been
demonstrated that cryopreserved microencapsulated hepato-
cytes retain gene expression of organic ion transporter 22
and CYP3A2/9.8 The results in the present study also
showed that cryopreserved HMBs had higher albumin pro-
duction than fresh HMBs at all times. The viability and
functionality of cryopreserved HMBs were maintained over
7 d while those of fresh HMBs continued to decrease. The
reason for this is unknown; however, it has been postulated
that cryopreservation “selects” only good quality hepato-
cytes which are viable on thawing.13 UW-based freezing
solution was chosen as a basal freezing medium for further
experiments, as it has been widely used in clinical transplan-
tation and is less expensive than CryoStor CS10. In this
study, 3 cytoprotectants targeting different sites of
cryopreservation-induced cell death in cryopreserved hepa-
tocyte microbeads were studied. The results demonstrated
that ZVAD had positive effects on cell viability and func-
tionality of RMBs when this cytoprotectant was added to the
basal freezing media. The beneficial effects on cell viability
were greater than with either DFO or HSA. This was shown
by both overall mitochondrial activity and fluorescent stain-
ing for viable cells. RMBs cryopreserved with ZVAD had a
reduction in cell apoptosis observed on TEM following cryo-
preservation when compared to basal freezing media alone
or other cytoprotectant groups. This was also supported by
the PI staining (DNA defragmentation)/FACS, which
showed that the sub-G1 cell population was lowest in the
ZVAD group. After thawing, ZVAD also reduced the degree
of apoptosis, but this was not as effective as including it in
the freezing medium. A possible explanation is that the pro-
cess of apoptosis has already started at the time of hepatocyte
isolation and continues throughout cryopreservation and
after thawing. Therefore, the earlier the addition of the
anti-apoptosis agent, the more beneficial effects will be
observed. The current data are consistent with previously
published studies showing the beneficial effects of ZVAD
when used in cryopreservation and cold storage.11,15 It is
worth mentioning that the cytoprotective effects of ZVAD
are dose-dependent and related to the cell type to be pre-
served and 60 mM was the optimal dose for hepatocytes.17
The addition of HSA showed some beneficial effects on
cell viability and function. In fact, HSA seemed to be a good
additive, as it has a buffering capacity and reduced DMSO
toxicity which may have protected cells from apoptosis.
Addition of HSA to the freezing medium is believed to be
beneficial not only for the cells but also for the physical
integrity of microbeads as well.20 Importantly, it is widely
used and clinically approved. However, the results obtained
showed that HSA was not as effective as ZVAD. This could
be due to the concentration used being too low (2% v/v) to
overcome the stress during cryopreservation and postthaw.
There have been no previously reported studies using HSA
for cryopreservation of microbeads. Similar to HSA, DFO
also had positive effects on cryopreserved RMBs but less
than ZVAD. The reason could be that a suboptimal concen-
tration of DFO was used in this study. DFO has been
reported to be effective in the reduction of necrosis and
apoptosis of hepatocytes during cold storage by reducing
reactive oxygen species associated with an increased intra-
cellular chelatable iron.19,46 DFO was one of the choices as a
cytoprotectant compound due to its properties and being
approved for clinical use. The testing of various concentra-
tions of HSA and DFO and the possible synergistic effects
when added together with ZVAD (HSA-ZVAD, DFO-
ZVAD, or HSA-DFO-ZVAD) to the cryopreservation media
at the same time would be important for future studies. It
must be noted that this set of experiments was done using
only RMBs due to the lack of good quality fresh human
hepatocytes at that time. Nevertheless, the initial results
showed similar outcomes using both human and rat hepato-
cytes. The results obtained from this study could be consid-
ered as an important step in the development of an optimized
protocol for cryopreservation of HMBs for clinical use.
In conclusion, cryopreservation of hepatocyte microbeads
using UW solution containing 10% DMSO, 5% glucose, and
a cytoprotectant such as ZVAD were shown to have bene-
ficial effects on cellular and physical damage leading to
maintenance of cell viability and function post thawing. This
initial optimization protocol for cryopreservation of hepato-
cyte microbeads supports the hypothesis that the
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development of freezing solution containing cryoprotective
agents and compounds targeting apoptosis during the cryo-
preservation process could improve the outcome of cryopre-
servation. We believe that clinically a large amount of
hepatocyte microbeads may be required immediately for
emergency treatment in conditions such as ALF. Establish-
ment of a bank of cryopreserved clinical grade hepatocyte
microbeads is an important goal.
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